Evidence map›Paper›PMID 26703963›Full record

Trial reportHaematologica2016

Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study.

Morgane Cheminant, Coralie Derrieux, Aurore Touzart, Stéphanie Schmit, Adrien Grenier, Amélie Trinquand, Marie-Hélène Delfau-Larue, Ludovic Lhermitte, Catherine Thieblemont, Vincent Ribrag and 10 more

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Haematologica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 57 citations in OpenAlex.

  1. Trial
  2. Measurable Residual Disease.Methods in molecular biology (Clifton, N.J.) · 2027
    Article
  3. Article
  4. Article
  5. Article
  6. Flow Cytometric MRD Detection in Selected Mature B-Cell Malignancies.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Stance of MRD in Non-Hodgkin's Lymphoma and its upsurge in the novel era of cell-free DNA.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021
    Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 12 institutions in 2 countries.

Morgane CheminantBiological Hematology, Paris Descartes - Sorbonne Paris Cité University, Institut Necker-Enfants Malades, AP-HP, France Clinical Hematology, Paris Descartes - Sorbonne Paris Cité University, IMAGINE Institut, Necker Hospital, AP-HP, France.
Coralie DerrieuxBiological Hematology, Paris Descartes - Sorbonne Paris Cité University, Institut Necker-Enfants Malades, AP-HP, France.
Aurore TouzartBiological Hematology, Paris Descartes - Sorbonne Paris Cité University, Institut Necker-Enfants Malades, AP-HP, France.
Stéphanie SchmitBiological Hematology, Paris Descartes - Sorbonne Paris Cité University, Institut Necker-Enfants Malades, AP-HP, France.
Adrien GrenierBiological Hematology, Paris Descartes - Sorbonne Paris Cité University, Institut Necker-Enfants Malades, AP-HP, France.
Amélie TrinquandBiological Hematology, Paris Descartes - Sorbonne Paris Cité University, Institut Necker-Enfants Malades, AP-HP, France.
Marie-Hélène Delfau-LarueBiological Hematology and Immunology, AP-HP, Groupe Hospitalier Mondor, Créteil, France.
Ludovic LhermitteBiological Hematology, Paris Descartes - Sorbonne Paris Cité University, Institut Necker-Enfants Malades, AP-HP, France.
Catherine ThieblemontHemato-Oncology, Saint-Louis Hospital, APHP - Paris Diderot - Sorbonne Paris Cité University - INSERM U728 - Institut Universitaire d'Hematologie, France.
Vincent RibragDépartement de Médecine, Institut Gustave Roussy, Villejuif, France.
Stéphane ChezeClinical Hematology, University Hospital of Caen, France.
Laurence SanhesClinical Hematology, Perpignan Hospital, France.
Fabrice JardinClinical Hematology, INSERM U918, IRIB, Centre Henri Becquerel, Rouen, France.
François LefrèreClinical Hematology, Paris Descartes - Sorbonne Paris Cité University, IMAGINE Institut, Necker Hospital, AP-HP, France.
Richard DelarueClinical Hematology, Paris Descartes - Sorbonne Paris Cité University, IMAGINE Institut, Necker Hospital, AP-HP, France.
Eva HosterInstitute of Medical Informatics, Biometry, and Epidemiology, University of Munich, Germany Department of Internal Medicine III, University Hospital Munich, Germany.
Martin DreylingDepartment of Internal Medicine III, University Hospital Munich, Germany.
Vahid AsnafiBiological Hematology, Paris Descartes - Sorbonne Paris Cité University, Institut Necker-Enfants Malades, AP-HP, France.
Olivier HermineClinical Hematology, Paris Descartes - Sorbonne Paris Cité University, IMAGINE Institut, Necker Hospital, AP-HP, France.
Elizabeth MacintyreBiological Hematology, Paris Descartes - Sorbonne Paris Cité University, Institut Necker-Enfants Malades, AP-HP, France elizabeth.macintyre@aphp.fr.
Université Paris Cité · FRAssistance Publique – Hôpitaux de Paris · FRSorbonne Paris Cité · FRCentre Henri BecquerelCentre Hospitalier de Perpignan · FRCentre Hospitalier Universitaire Henri-Mondor · FRDélégation Paris 5 · FRInstitut Gustave Roussy · FRInstitut Necker Enfants Malades · FRMünchen Klinik · DEUniversité de Caen Normandie · FRZimmer Biomet (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Quantification of minimal residual disease may guide therapeutic strategies in mantle cell lymphoma. While multiparameter flow cytometry is used for diagnosis, the gold standard method for minimal residual disease analysis is real-time quantitative polymerase chain reaction (RQ-PCR). In this European Mantle Cell Lymphoma network (EU-MCL) pilot study, we compared flow cytometry with RQ-PCR for minimal residual disease detection. Of 113 patients with at least one minimal residual disease sample, RQ-PCR was applicable in 97 (86%). A total of 284 minimal residual disease samples from 61 patients were analyzed in parallel by flow cytometry and RQ-PCR. A single, 8-color, 10-antibody flow cytometry tube allowed specific minimal residual disease assessment in all patients, with a robust sensitivity of 0.01%. Using this cut-off level, the true-positive-rate of flow cytometry with respect to RQ-PCR was 80%, whereas the true-negative-rate was 92%. As expected, RQ-PCR frequently detected positivity below this 0.01% threshold, which is insufficiently sensitive for prognostic evaluation and would ideally be replaced with robust quantification down to a 0.001% (10-5) threshold. In 10 relapsing patients, the transition from negative to positive by RQ-PCR (median 22.5 months before relapse) nearly always preceded transition by flow cytometry (4.5 months), but transition to RQ-PCR positivity above 0.01% (5 months) was simultaneous. Pre-emptive rituximab treatment of 2 patients at minimal residual disease relapse allowed re-establishment of molecular and phenotypic complete remission. Flow cytometry minimal residual disease is a complementary approach to RQ-PCR and a promising tool in individual mantle cell lymphoma therapeutic management. (clinicaltrials identifiers: 00209209 and 00209222).

Indexed as

AdultAgedAntigens, CDAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorFemaleFlow CytometryHumansImmunophenotypingLymphoma, Mantle-CellMaleMiddle AgedNeoplasm, ResidualPilot ProjectsPrognosisReal-Time Polymerase Chain ReactionAntigens, CDBiomarkers, Tumor

Identifiers

PMID26703963
PMCPMC4815725
OpenAlexW2239959579

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.